HIV-1 vaccines: The search continues

Clinics in Laboratory Medicine

Volumn 22, Issue 3, 2002, Pages 799-820

  McGettigan, James P ^a   McKenna, Philip M ^a   Schnell, Matthias J ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS PROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; CLINICAL RESEARCH; CYTOTOXIC T LYMPHOCYTE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LENTIVIRINAE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION;

AIDS VACCINES; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNIZATION; VACCINES, SYNTHETIC;

EID: 0036716846     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-2712(02)00004-5     Document Type: Review

References (182)

1. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS
2. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection
3. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
4. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
5. Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors
6. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
7. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
8. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
9. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients
10. Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection
11. Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development
12. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals
13. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS
14. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: A rationale for the use of Tat toxoid as an HIV-1 vaccine
15. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques
16. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
17. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees
18. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
19. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
20. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
21. Six decades of vaccine development: A personal history
22. Vaccine protection against simian immunodeficiency virus infection
23. A formalin-inactivated whole SIV vaccine confers protection in macaques
24. Immunization with tween-ether-treated SIV adsorbed onto aluminum hydroxide protects monkeys against experimental SIV infection
25. Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus
26. The ability of certain SIV vaccines to provoke reactions against normal cells
27. Anti-cell antibody in macaques
28. Neither whole inactivated virus immunogen nor passive immunoglobulin transfer protects against SIVagm infection in the African green monkey natural host
29. Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2
30. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1
31. Primate models for HIV vaccines
32. Animal models of AIDS
33. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: Experience of the NIAID AIDS Vaccine Evaluation Group
34. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers
35. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59
36. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
37. HIV infection in vaccinated volunteers
38. Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial
39. Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection: Potential mechanism of vaccine failure
40. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen
41. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320
42. Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits
43. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein
44. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions
45. Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-1IIIB GP120 peptide RP135
46. Structural comparison of a 15 residue peptide from the V3 loop of HIV-1IIIb and an O-glycosylated analogue
47. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure
48. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine
49. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
50. Mutations in the membrane-spanning domain of the human immunodeficiency virus envelope glycoprotein that affect fusion activity
51. Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts
52. Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus type 1 DNA plasmid vaccines to pregnant chimpanzees
53. Genetic vaccines
54. Genetic immunization is a simple method for eliciting an immune response
55. Vaccination against tuberculosis by DNA injection
56. Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene
57. Heterologous protection against influenza by injection of DNA encoding a viral protein
58. Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA
59. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression
60. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene
61. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination
62. Simian immunodeficiency virus DNA vaccine trial in macaques
63. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160
64. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
65. Fetal or neonatal infection with attenuated simian immunodeficiency virus results in protective immunity against oral challenge with pathogenic SIVmac251
66. Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV
67. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
68. Importance of the nef gene for maintenance of high virus loads and for development of AIDS
69. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells
70. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques
71. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
72. Safety issues facing development of a live-attenuated, multiply deleted HIV-1 vaccine
73. Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain
74. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines
75. Development of a BCG recombinant vehicle for candidate AIDS vaccines
76. Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector
77. Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques
78. Viral vectors as potential HIV-1 vaccines
79. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
80. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults
81. Canarypox virus-based vaccines: Prime-boost strategies to induce cell-mediated and humoral immunity against HIV
82. Search for a HIV vaccine
83. Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees
84. Simian immunodeficiency virus (SIV) gp130 oligomers protect rhesus macaques (Macaca mulatta) against the infection with SIVmac32H grown on T-cells or derived ex vivo
85. Recombinant subunit vaccines as an approach to study correlates of protection against primate lentivirus infection
86. Protection of vaccinia-primed macaques against SIVmne infection by combination immunization with recombinant vaccinia virus and SIVmne gp160
87. Evaluation of protective efficacy of recombinant subunit vaccines against simian immunodeficiency virus infection of macaques
88. Protection against human immunodeficiency virus type 2 and simian immunodeficiency virus in macaques vaccinated against human immunodeficiency virus type 2
89. Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys
90. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques
91. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) gag-Pol and/or env in macaques challenged with pathogenic SIV
92. Cytokines from vaccine-induced HIV-1 specific cytotoxic T lymphocytes: Effects on viral replication
93. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein
94. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans
95. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene
96. Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines
97. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine
98. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines
99. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen
100. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model
101. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization
102. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration
103. Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251
104. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge
105. Replication-incompetent recombinant adenovirus vector expressing SIV gag elicits robust and effective cellular immune responses in rhesus macaques
106. Preclinical evaluation of gene-delivery-based HIV-1 vaccines in nonhuman primates
107. The use of picornaviruses as vectors for the engineering of live recombinant vaccines
108. Study of the immunogenicity of different recombinant Mengo viruses expressing HIV1 and SIV epitopes
109. Attenuated Mengo virus as a vector for immunogenic human immunodeficiency virus type 1 glycoprotein 120
110. Human rhinovirus type 14: Human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1
111. Chimeras from a human rhinovirus 14-human immunodeficiency virus type 1 (HIV-1) V3 loop seroprevalence library induce neutralizing responses against HIV-1
112. T- and B-lymphocyte responses to human immunodeficiency virus (HIV) type 1 in macaques immunized with hybrid HIV/hepatitis B surface antigen particles
113. Construction and genetic analysis of dicistronic polioviruses containing open reading frames for epitopes of human immunodeficiency virus type 1 gp120
114. A poliovirus replicon containing the chloramphenicol acetyltransferase gene can be used to study the replication and encapsidation of poliovirus RNA
115. Encapsidation of poliovirus replicons encoding the complete human immunodeficiency virus type 1 gag gene by using a complementation system which provides the P1 capsid protein in trans
116. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine
117. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
118. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus
119. RNA virus vectors: Where are we and where do we need to go?
120. Immunogenicity of recombinant influenza virus haemagglutinin carrying peptides from the envelope protein of human immunodeficiency virus type 1
121. Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates
122. Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector
123. Recombinant rabies virus as potential live-viral vaccines for HIV-1
124. A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection
125. Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells
126. Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins
127. Vaccination with VSV G protein exchange vactors expressing HIV Env and SIV Gag proteins protects rhesus macaques from challenge with highly pathogenic SHIV 89.6P
128. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants
129. Sendai virus-based production of HIV type 1 subtype B and subtype E envelope glycoprotein 120 antigens and their use for highly sensitive detection of subtype-specific serum antibodies
130. Measles vaccine as a potential vector for AIDS vaccination
131. Recombinant Newcastle disease virus as a vaccine vector
132. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
133. DNA vaccines for immunodeficiency viruses
134. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1
135. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
136. Imperfect vaccines and the evolution of pathogen virulence
137. The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12
138. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza
139. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections
140. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians
141. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein
142. Humoral immune response elicited by highly attenuated variants of vaccinia virus and by an attenuated recombinant expressing HIV-1 envelope protein
143. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation
144. Human studies in the development of human immunodeficiency virus vaccines
145. Prime-boost immunization strategies against HIV
146. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees
147. Adenovirus vectored vaccines
148. Adenovirus as vector for HIV: Efficacy and safety issues
149. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus
150. SV40 as a vector for immunization against lentiviral envelope glycoproteins
151. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors
152. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: Stimulation of humoral, mucosal, and cellular immunity
153. Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes
154. Libraries of human rhinovirus-based HIV vaccines generated using random systematic mutagenesis
155. A therapeutic HIV vaccine using coxsackie-HIV recombinants: A possible new strategy
156. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector
157. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus
158. Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants
159. Mucosal model of immunization against human immunodeficiency virus type 1 with chimeric influenza virus
160. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria
161. New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview
162. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice
163. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime
164. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS
165. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of pre-existing immunity to the vector
166. Recombinant modified vaccinia virus Ankarasimian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer
167. Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions
168. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
169. Efficient human immunodeficiency virus (HIV)-1 Gag-Env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate
170. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
171. Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: Implications for antigen-specific immunotherapy
172. Canarypox as a vector for HIV vaccine [news]
173. Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus
174. Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies
175. Applications of pox virus vectors to vaccination: An update
176. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI)
177. The safety and use of canarypox vectored vaccines
178. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection
179. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
180. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: Vector design strategies for improved vaccine efficacy
181. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo
182. Immune responses induced by administration of encapsidated poliovirus replicons which express HIV-1 gag and envelope proteins